To examine whether CD19@NP/17-DMAG with imatinib is more effective than 17-DMAG plus imatinib alone (Figure 4A), we employed a previously described murine BCR-ABL1+ B-ALL model 23, which mirrors patient-derived Ph+ B-ALL through the rapid proliferation of CD19+ GFP+ leukemic cells in the bone marrow and secondary lymphoid organs (Figure S4A-C). This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.